Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in Advanced Transitional Cell Carcinoma of the Urothelium
NCT00066612Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Jul 2003
- Primary completion
- Aug 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in transitional cell carcinoma of the urothelium (TCC), sponsored by SWOG Cancer Research Network. Started Jul 2003; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
transitional cell carcinoma of the urothelium (TCC)
Beyond the preview
Go deeper on NCT00066612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00066612.